CBP/p300 Dual Inhibitors for cBAF-Deficient Cancers
Author Information
Author(s): Sasaki Mariko, Kato Daiki, Yoshida Hiroshi, Shimizu Takafumi, Ogiwara Hideaki
Primary Institution: National Cancer Center Research Institute, Tokyo, Japan
Hypothesis
Can CBP/p300 dual inhibitors induce synthetic lethality in cBAF-deficient cancers?
Conclusion
CBP/p300 dual inhibitors effectively induce apoptosis in cBAF-deficient cancers by downregulating KREMEN2.
Supporting Evidence
- CBP/p300 dual inhibitors caused synthetic lethality in cBAF-deficient cancer cells.
- Treatment with CBP/p300 inhibitors led to downregulation of KREMEN2 and increased apoptosis.
- Xenograft models showed significant tumor suppression with CBP/p300 inhibitors.
Takeaway
This study shows that a special type of medicine can help treat certain cancers by making them die when two proteins are blocked at the same time.
Methodology
The study used cell lines and mouse xenograft models to test the effects of CBP/p300 dual inhibitors on cancer cell viability and apoptosis.
Potential Biases
Potential bias in the selection of cell lines and the interpretation of results.
Limitations
The study primarily focuses on specific cancer types and may not generalize to all cancers.
Participant Demographics
The study involved various cancer cell lines, including those deficient in specific SWI/SNF complex components.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website